A citation-based method for searching scientific literature

Sophia Yohe, Bharat Thyagarajan. Arch Pathol Lab Med 2017
Times Cited: 102







List of co-cited articles
429 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Isaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, Charlotte Ng, Sarah Hrebien, Rosalind J Cutts, Maggie Cheang, Peter Osin, Ashutosh Nerurkar, Iwanka Kozarewa,[...]. Sci Transl Med 2015
593
3

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
3

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
573
3

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
Valerie Taly, Deniz Pekin, Leonor Benhaim, Steve K Kotsopoulos, Delphine Le Corre, Xinyu Li, Ivan Atochin, Darren R Link, Andrew D Griffiths, Karine Pallier,[...]. Clin Chem 2013
315
3


Age-related mutations associated with clonal hematopoietic expansion and malignancies.
Mingchao Xie, Charles Lu, Jiayin Wang, Michael D McLellan, Kimberly J Johnson, Michael C Wendl, Joshua F McMichael, Heather K Schmidt, Venkata Yellapantula, Christopher A Miller,[...]. Nat Med 2014
913
3

Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
Stefania Morganti, Paolo Tarantino, Emanuela Ferraro, Paolo D'Amico, Giulia Viale, Dario Trapani, Bruno Achutti Duso, Giuseppe Curigliano. Crit Rev Oncol Hematol 2019
29
10

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
515
3

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
3

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
464
3

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.
Manfred Dietel, Lukas Bubendorf, Anne-Marie C Dingemans, Christophe Dooms, Göran Elmberger, Rosa Calero García, Keith M Kerr, Eric Lim, Fernando López-Ríos, Erik Thunnissen,[...]. Thorax 2016
83
3

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
Keith Nykamp, Michael Anderson, Martin Powers, John Garcia, Blanca Herrera, Yuan-Yuan Ho, Yuya Kobayashi, Nila Patil, Janita Thusberg, Marjorie Westbrook,[...]. Genet Med 2017
207
3

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
3

Comparison of next-generation sequencing systems.
Lin Liu, Yinhu Li, Siliang Li, Ni Hu, Yimin He, Ray Pong, Danni Lin, Lihua Lu, Maggie Law. J Biomed Biotechnol 2012
616
3

Clinical sequencing: From raw data to diagnosis with lifetime value.
S M Caspar, N Dubacher, A M Kopps, J Meienberg, C Henggeler, G Matyas. Clin Genet 2018
39
7

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
70
4

The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community.
Miten Jain, Hugh E Olsen, Benedict Paten, Mark Akeson. Genome Biol 2016
382
2


EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
2

Characterization of individual polynucleotide molecules using a membrane channel.
J J Kasianowicz, E Brandin, D Branton, D W Deamer. Proc Natl Acad Sci U S A 1996
2

Liquid biopsy: unlocking the potentials of cell-free DNA.
David Chu, Ben Ho Park. Virchows Arch 2017
24
8

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
2


TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Klaus H Metzeler, Kati Maharry, Michael D Radmacher, Krzysztof Mrózek, Dean Margeson, Heiko Becker, John Curfman, Kelsi B Holland, Sebastian Schwind, Susan P Whitman,[...]. J Clin Oncol 2011
237
2

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, Marianne Habdank, Jan Krönke, Lars Bullinger, Daniela Späth, Sabine Kayser, Manuela Zucknick, Katharina Götze,[...]. J Clin Oncol 2010
545
2

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Wen-Chien Chou, Sheng-Chieh Chou, Chieh-Yu Liu, Chien-Yuan Chen, Hsin-An Hou, Yuan-Yeh Kuo, Ming-Cheng Lee, Bor-Sheng Ko, Jih-Luh Tang, Ming Yao,[...]. Blood 2011
194
2

SIFT: Predicting amino acid changes that affect protein function.
Pauline C Ng, Steven Henikoff. Nucleic Acids Res 2003
2

Cost analysis of whole genome sequencing in German clinical practice.
Marika Plöthner, Martin Frank, J-Matthias Graf von der Schulenburg. Eur J Health Econ 2017
17
11

Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.
Lídia Feliubadaló, Raúl Tonda, Mireia Gausachs, Jean-Rémi Trotta, Elisabeth Castellanos, Adriana López-Doriga, Àlex Teulé, Eva Tornero, Jesús Del Valle, Bernat Gel,[...]. Sci Rep 2017
24
8

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
939
2

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Andreas Hochhaus, Richard A Larson, François Guilhot, Jerald P Radich, Susan Branford, Timothy P Hughes, Michele Baccarani, Michael W Deininger, Francisco Cervantes, Satoko Fujihara,[...]. N Engl J Med 2017
434
2

Genome sequencing: a systematic review of health economic evidence.
Martin Frank, Anne Prenzler, Roland Eils, J-Matthias Graf von der Schulenburg. Health Econ Rev 2013
35
5

Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Geraldine O'Sullivan Coyne, Naoko Takebe, Alice P Chen. Curr Probl Cancer 2017
52
3

Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
Holly LaDuca, Kelly D Farwell, Huy Vuong, Hsiao-Mei Lu, Wenbo Mu, Layla Shahmirzadi, Sha Tang, Jefferey Chen, Shruti Bhide, Elizabeth C Chao. PLoS One 2017
43
4

The real cost of sequencing: higher than you think!
Andrea Sboner, Xinmeng Jasmine Mu, Dov Greenbaum, Raymond K Auerbach, Mark B Gerstein. Genome Biol 2011
188
2

First FDA authorization for next-generation sequencer.
Francis S Collins, Margaret A Hamburg. N Engl J Med 2013
121
2

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
B J Druker, M Talpaz, D J Resta, B Peng, E Buchdunger, J M Ford, N B Lydon, H Kantarjian, R Capdeville, S Ohno-Jones,[...]. N Engl J Med 2001
2

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
219
2

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Anne C Harttrampf, Ludovic Lacroix, Marc Deloger, Frederic Deschamps, Stephanie Puget, Nathalie Auger, Philippe Vielh, Pascale Varlet, Zsofia Balogh, Samuel Abbou,[...]. Clin Cancer Res 2017
41
4

Debunking the Delusion That Precision Oncology Is an Illusion.
Vivek Subbiah, Razelle Kurzrock. Oncologist 2017
13
15


Personalized oncology through integrative high-throughput sequencing: a pilot study.
Sameek Roychowdhury, Matthew K Iyer, Dan R Robinson, Robert J Lonigro, Yi-Mi Wu, Xuhong Cao, Shanker Kalyana-Sundaram, Lee Sam, O Alejandro Balbin, Michael J Quist,[...]. Sci Transl Med 2011
424
2

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
550
2

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.
Anath C Lionel, Gregory Costain, Nasim Monfared, Susan Walker, Miriam S Reuter, S Mohsen Hosseini, Bhooma Thiruvahindrapuram, Daniele Merico, Rebekah Jobling, Thomas Nalpathamkalam,[...]. Genet Med 2018
176
2

Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes.
Tony Shen, Stefan Hans Pajaro-Van de Stadt, Nai Chien Yeat, Jimmy C-H Lin. Front Genet 2015
55
3

A new initiative on precision medicine.
Francis S Collins, Harold Varmus. N Engl J Med 2015
2

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Vladimir Lazar, Brian Leyland-Jones, Richard L Schilsky, John Mendelsohn, Razelle Kurzrock. JAMA Oncol 2016
146
2


Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology.
Linda M Sabatini, Charles Mathews, Devon Ptak, Shivang Doshi, Katherine Tynan, Madhuri R Hegde, Tara L Burke, Aaron D Bossler. J Mol Diagn 2016
51
3

Tissue-based next generation sequencing: application in a universal healthcare system.
Seán O Hynes, Brendan Pang, Jacqueline A James, Perry Maxwell, Manuel Salto-Tellez. Br J Cancer 2017
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.